<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02218359</url>
  </required_header>
  <id_info>
    <org_study_id>CAP-01-103</org_study_id>
    <nct_id>NCT02218359</nct_id>
  </id_info>
  <brief_title>Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization</brief_title>
  <official_title>A Randomized Double-Blind, Placebo-Controlled, Crossover to Open Label, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® AFIS Inline System in Mechanically Ventilated Patients With Gram-negative and/or Gram-positive Bacterial Colonization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardeas Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardeas Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety and efficacy of adjunctive therapy with the Amikacin Fosfomycin
      Inhalation System (AFIS) versus aerosolized placebo in mechanically ventilated patients with
      Gram-negative and / or Gram-positive bacterial colonization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to demonstrate the safety and efficacy of the amikacin
      fosfomycin inhalation system (AFIS). AFIS consists of amikacin solution (AMS) and fosfomycin
      solution (FFS), delivered by aerosol to the lungs via the Investigational eFlow AFIS Inline
      System (AFIS Inline System) with tamper evident reservoir. Patients will be randomized to
      receive 5 days of treatment with either AFIS or placebo, followed by all patients receiving
      open label AFIS for five days. The primary efficacy endpoint is the change from baseline in
      tracheal aspirate Gram-negative and/or Gram-positive bacterial density at the end of the
      5-day randomized course of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No Participants Enrolled
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in tracheal aspirate Gram-negative and Gram-positive bacterial density</measure>
    <time_frame>5 day randomized course of study drug</time_frame>
    <description>Change from baseline in tracheal aspirate Gram-negative and Gram-positive bacterial density at the end of the 5-day randomized course of study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological response rate in patients with multidrug resistant Gram-negative bacteria</measure>
    <time_frame>Day 5</time_frame>
    <description>Microbiological response rates at Day 5 in patients whose pre-study treatment tracheal aspirate culture was positive for multidrug resistant (MDR) Gram-negative bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of bacteria</measure>
    <time_frame>Days 10, 21, and 28</time_frame>
    <description>Eradication of bacteria at Days 10, 21, and 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical worsening</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <description>Clinical worsening (defined as requiring institution of IV antibiotics) from Day 1 through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response rates</measure>
    <time_frame>Day 10</time_frame>
    <description>Microbiological response rates at Day 10 in all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response rates in patients with MRSA</measure>
    <time_frame>Day 5</time_frame>
    <description>Microbiological response rates at Day 5 in patients whose pre-study treatment tracheal aspirate culture was positive for methicillin resistant Staphylococcus aureus (MRSA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pneumonia, Bacterial</condition>
  <arm_group>
    <arm_group_label>Amikacin Fosfomycin Inhalation Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of amikacin and 120 mg of fosfomycin to be administered by aerosol via the AFIS Inline System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aerosolized placebo to be administered by aerosol using the AFIS Inline System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amikacin Fosfomycin Inhalation Solution</intervention_name>
    <description>300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System</description>
    <arm_group_label>Amikacin Fosfomycin Inhalation Solution</arm_group_label>
    <other_name>Amikacin Fosfomycin Inhalation System (AFIS)</other_name>
    <other_name>eFlow Inline System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerosolized placebo</intervention_name>
    <description>Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.</description>
    <arm_group_label>Aerosolized Placebo</arm_group_label>
    <other_name>eFlow Inline System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amikacin Fosfomycin Inhalation Solution</intervention_name>
    <description>Open-label crossover for all patients Days 6-10</description>
    <arm_group_label>Amikacin Fosfomycin Inhalation Solution</arm_group_label>
    <arm_group_label>Aerosolized Placebo</arm_group_label>
    <other_name>Amikacin Fosfomycin Inhalation System (AFIS)</other_name>
    <other_name>eFlow Inline System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant, non-lactating females, ≥ 18 years and ≤ 80 years of age

          -  Intubated and mechanically-ventilated

          -  Presence of Gram-negative and/or Gram-positive organism(s) by culture of respiratory
             secretions from a sample obtained within the previous 7 days

        Exclusion Criteria:

          -  History of hypersensitivity to amikacin or fosfomycin.

          -  Diagnosis of pneumonia, defined as presence of a new or progressive infiltrate(s) on
             chest radiograph (within 7 days prior to screening), as determined by the treating
             physician

          -  Use of systemic antibiotics with efficacy against likely respiratory tract pathogens
             at the time of randomization

          -  Severe acute respiratory distress syndrome (defined as PaO2/FiO2 ≤ 100 mmHg and
             diffuse infiltrates on Chest X-ray)

          -  Refractory septic shock (severe sepsis plus unstable hypotension, in spite of adequate
             fluid resuscitation and vasopressors)

          -  Evidence of significant renal impairment (serum creatinine &gt; 4.0 mg/dL within 24 hours
             prior to screening) . If serum creatinine is &gt; 2.0 mg/dL, site must be capable of
             performing continuous renal replacement therapy, if clinically indicated. Patients
             with serum creatinine &gt; 4.0 mg/dL and being treated with continuous renal replacement
             therapy (continuous venous-venous hemofiltration or continuous venous-venous
             hemodialysis) or chronic hemodialysis are eligible

          -  Evidence of ototoxicity (history of hearing aid use prior to current hospitalization)

          -  Evidence of hepatotoxicity (alanine aminotransferase [ALT] or aspartate
             aminotransferase [AST] &gt; 3X the upper limit of normal value within 24 hours prior to
             screening)

          -  Any of the following conditions that interfere with the assessment or interpretation
             of the diagnosis or response to therapy: chest trauma with loss of stability of the
             thoracic cage following a fracture of the sternum, ribs, or both; increased amounts of
             fluid in the lung cavities requiring chest tube drainage; lung cancer within the last
             2 years; lung abscess(s); anatomical bronchial obstruction; suspected atypical
             pneumonia; chemical pneumonitis (e.g., inhalation injury); cystic fibrosis; congestive
             heart failure (leading to a PaO2/FiO2 ratio ≤ 100 mmHg and diffuse infiltrates on
             Chest X-ray)

          -  Immunocompromised patients, including those with neutropenia NOT due to the current
             infection (absolute neutrophil count &lt; 500/mm³), leukemia, lymphoma, human
             immunodeficiency virus (HIV) infection with CD4 count &lt; 200 cells/mm3, or splenectomy;
             those who are early post-transplantation, are on cytotoxic chemotherapy, or are on
             high-dose steroids (e.g., &gt; 40 mg of prednisone or its equivalent [&gt; 160 mg
             hydrocortisone, &gt; 32 mg methylprednisolone, &gt; 6 mg dexamethasone, &gt; 200 mg cortisone]
             daily for &gt; 2 weeks)

          -  Positive urine and/or serum beta-hCG pregnancy test (only in women of reproductive
             age)

          -  Participating in or has participated in other investigational interventional studies
             (drug or device) within the last 30 days (or 5 times the half-life of the previously
             administered investigational compound, whichever is longer) prior to study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Montgomery, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cardeas Pharma</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/antibiotics.html</url>
    <description>MedlinePlus related topics: Antibiotics</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/pneumonia.html</url>
    <description>MedlinePlus related topics: Pneumonia</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0037517285&amp;QV1=AMIKACIN</url>
    <description>Drug Information available for amikacin</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0023155024&amp;QV1=FOSFOMYCIN</url>
    <description>Drug information available for fosfomycin</description>
  </link>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2014</study_first_submitted>
  <study_first_submitted_qc>August 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2014</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram-negative pneumonia</keyword>
  <keyword>Aerosol antibiotics</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Amikacin</keyword>
  <keyword>Fosfomycin</keyword>
  <keyword>Pneumonia, Bacterial</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>MRSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

